Long noncoding RNA ANRIL regulates proliferation of non-small cell lung cancer and cervical cancer cells

Anticancer Research

Volumn 35, Issue 10, 2015, Pages 5377-5382

  Naemura, Madoka ^a   Murasaki, Chihiro ^a   Inoue, Yasutoshi ^a   Okamoto, Haruna ^a   Kotake, Yojiro ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

ANRIL; Cell cycle; Long noncoding RNA; P15; P16

Indexed keywords

ANTISENSE NON CODING RNA CYCLIN DEPENDENT KINASE 4; LONG UNTRANSLATED RNA; PROTEIN P15; PROTEIN P16; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANRIL LONG NON-CODING RNA, HUMAN; CDKN2B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ARTICLE; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE ASSAY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FIBROBLAST; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAOS 2 CELL LINE; CELL CYCLE CHECKPOINT; GENETICS; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; FEMALE; HELA CELLS; HUMANS; LUNG NEOPLASMS; RNA, LONG NONCODING; UTERINE CERVICAL NEOPLASMS;

EID: 84942760825     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ruas M and Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-177, 1998.
2. Sharpless NE: INK4a/ARF: a multifunctional tumor-suppressor locus. Mutat Res 576: 22-38, 2005.
3. Aravidis C, Panani AD, Kosmaidou Z, Thomakos N, Rodolakis A and Antsaklis A: Detection of numerical abnormalities of chromosome 9 and p16/CDKN2A gene alterations in ovarian cancer with FISH analysis. Anticancer Res 32: 5309-5313, 2012.
4. Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, Andre P, Mely Y, Mousli M and Gies JP: CD47 Activation-induced UHRF1 overexpression is associated with silencing of tumor-suppressor gene p16INK4A in glioblastoma cells. Anticancer Res 35: 149-157, 2015.
5. Pei XH and Xiong Y: Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24: 2787-2795, 2005.
6. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
7. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T and Schmitt CA: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665, 2005.
8. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W and Peters G: INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 21: 2936-2945, 2002.
9. Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW: Oncogenic RAS provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602, 1997.
10. Kim WY and Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275, 2006.
11. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA: The INK4A tumor-suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998.
12. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014, 1998.
13. Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor-suppression pathways. Cell 92: 725-734, 1998.
14. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D and Bieche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression co-clusters with ARF. Cancer Res 67: 3963-3969, 2007.
15. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ and Zhou MM: Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662-674, 2010.
16. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M and Xiong Y: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumorsuppressor gene. Oncogene 30: 1956-1962, 2011.
17. Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, Finstermeier K, Stahringer A, Wilfert W, Beutner F, Gielen S, Schuler G, Gabel G, Bergert H, Bechmann I, Stadler PF, Thiery J and Teupser D: Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet 9: e1003588, 2013.
18. Sato K, Nakagawa H, Tajima A, Yoshida K and Inoue I: ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol Rep 24: 701-707, 2010.
19. Congrains A, Kamide K, Katsuya T, Yasuda O, Oguro R, Yamamoto K, Ohishi M and Rakugi H: CVD-associated noncoding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 419: 612-616, 2012.
20. Batista PJ and Chang HY: Long non-coding RNAs: cellular address codes in development and disease. Cell 152: 1298-1307, 2013.
21. Fatica A and Bozzoni I: Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15: 7-21, 2014.
22. Kitagawa M, Kotake Y and Ohhata T: Long non-coding RNAs involved in cancer development and cell fate determination. Curr Drug Targets 13: 1616-1621, 2012.
23. Kitagawa M, Kitagawa K, Kotake Y, Niida H and Ohhata T: Cell-cycle regulation by long non-coding RNAs. Cell Mol Life Sci 70: 4785-4794, 2013.
24. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W and Chen J: Long non-coding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5: 2276-2292, 2014.
25. Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G and Lu X: Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 25: 1086-1095, 2013.
26. Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: an exit from cell-cycle control. Nat Rev Cancer 9: 785-797, 2009.
27. Kotake Y, Naemura M, Kitagawa K, Niida H, Tsunoda T, Shirasawa S and Kitagawa M: Oncogenic Ras influences the expression of multiple lncRNAs. Cytotechnology, 2015, in press.